Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 12/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6691016 | 0.91 | HDAC1 (0.39) | HDAC1HDAC6CXCR4CYP3A4CYP2D6 | |
| SCHEMBL6018435 | 0.81 | HDAC1 (0.47) | HDAC1HDAC6CXCR4CYP3A4CYP2D6 | |
| SCHEMBL6018210 | 0.74 | CXCR4 (0.39) | HDAC1HDAC6CXCR4SLC40A1 | |
| SCHEMBL6019179 | 0.74 | HDAC1 (0.55) | HDAC1HDAC6CXCR4CYP3A4CYP2D6 | |
| SCHEMBL7024499 | 0.74 | HDAC1 (0.42) | HDAC1HDAC6CXCR4CYP3A4CYP2D6 | |
| SCHEMBL6687600 | 0.72 | HDAC1 (0.41) | HDAC1HDAC6CXCR4CYP3A4CYP2D6 | |
| SCHEMBL1874122 | 0.72 | HDAC1 (0.63) | HDAC1HDAC6CXCR4CYP3A4CYP2D6 | |
| SCHEMBL29823204 | 0.72 | HDAC1 (0.63) | HDAC1HDAC6CXCR4CYP3A4CYP2D6 | |
| SCHEMBL4065365 | 0.72 | HDAC1 (0.74) | HDAC1HDAC6CXCR4HPGDMEN1 | |
| SCHEMBL1882612 | 0.72 | HDAC1 (0.62) | HDAC1HDAC6CXCR4CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157818-A1 | Cxcr4-antagonistic drugs composed of nitrogen-containing compound | KUREHA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1389460-A1 | CXCR4-ANTAGONISTIC DRUGS COMPRISING NITROGEN-CONTAINING COMPOUND | Kureha Chemical Industry Co., Ltd. (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157818-A1 | Cxcr4-antagonistic drugs composed of nitrogen-containing compound | CXCR4, CXCR1, CXCR2 | HDAC1 1092/4885HDAC6 1799/4885CXCR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.